| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1366534 | Bioorganic & Medicinal Chemistry Letters | 2007 | 6 Pages |
Abstract
DPC168, a benzylpiperidine-substituted aryl urea CCR3 antagonist evaluated in clinical trials, was a relatively potent inhibitor of the 2D6 isoform of cytochrome P-450 (CYP2D6). Replacement of the cyclohexyl central ring with saturated heterocycles provided potent CCR3 antagonists with improved selectivity against CYP2D6. The favorable preclinical profile of DPC168 was maintained in an acetylpiperidine derivative, BMS-570520.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
James R. Pruitt, Douglas G. Batt, Dean A. Wacker, Lori L. Bostrom, Shon K. Booker, Erin McLaughlin, Gregory C. Houghton, Jeffrey G. Varnes, David D. Christ, Maryanne Covington, Anuk M. Das, Paul Davies, Danielle Graden, Ilona Kariv, Yevgeniya Orlovsky,